Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14337 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Martin Chandler und 4 weiteren Autor:innen. Beteiligte Einrichtung: American Thrombosis & Hemostasis Network, Rochester, New York, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.
Abstract (Originalsprache)
Objectives
Health information for 17 109 people living with hemophilia A (PLwHA) is contained within the ATHNdataset. We aimed to evaluate the real‐world effectiveness of damoctocog alfa pegol (BAY 94‐9027, Jivi®) for hemophilia A.
Methods
The ATHNdataset was queried for PLwHA receiving damoctocog alfa pegol between January 1, 2010 and April 30, 2022. Data captured via patient charts were analyzed.
Results
At data cutoff, 205 PLwHA were treated with damoctocog alfa pegol: 150 (73.2%) severe (1 female [0.5%]) and 55 (26.8%) mild/moderate (3 [1.5%] female). In total, 32/205 (25.9%) PLwHA received on‐demand treatment; 172 (83.9%) received prophylaxis—161 (93.6%) continuous prophylaxis. Documented bleed rates were available for 187 (91.2%) PLwHA, including those on prophylaxis and on‐demand regimens, with 150 (80.2%) treated for > 12 months. Overall annualized bleeding rates and proportion of PLwHA with zero bleeds, receiving prophylaxis during the observation period, were mean (SD) 0.26 (1.03) and 138/157 (87.9%), respectively. No new or recurring inhibitors were reported.
Conclusion
A low number of bleeds were observed with damoctocog alfa pegol in the real world in both male and female PLwHA. Data should be interpreted with caution owing to limitations of real‐world studies and insubstantial data for female PLwHA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- American Thrombosis & Hemostasis Network, Rochester, New York, USA.
- Bayer U.S. LLC, Whippany, New Jersey, USA.
- Yale University School of Medicine, New Haven, Connecticut, USA.
Förderung
- Bayer
Zitieren
APA
Chandler, M., Moulton, T., Charafi, L., Charlet, J., & Recht, M. (2025). Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal of Haematology. https://doi.org/10.1111/ejh.14337
Vancouver
Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal of Haematology. 2025. doi:10.1111/ejh.14337
BibTeX
@article{Chandler2025,
author = {Chandler, Martin and Moulton, Thomas and Charafi, Lena and Charlet, Jessica and Recht, Michael},
title = {Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14337}
}
EUVIMED